We advised the underwriters on the IPO and Nasdaq listing

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 13,225,000 shares of common stock of Bolt Biotherapeutics, Inc. at $20.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 1,725,000 additional shares), for total gross proceeds of $230 million. Bolt’s common stock is listed on the Nasdaq Global Select Market under the symbol “BOLT.”

Bolt is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s Boltbody ISAC approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems. Bolt Biotherapeutics, Inc. is headquartered in Redwood City, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Bryan M. Quinn and Lawrence Edward Traylor Jr. Partner Po Sit and associate Joseph M. Gerstel provided tax advice. Partner David R. Bauer and associates Hilary Smith and Brette L. Trost provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post